JJJuan Jakez-Ocampo

Juan Jakez-Ocampo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Juan Jakez-Ocampo has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Luis Llorente

    Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City 14000, Mexico

    3 shared publications
  • G. Lima

    Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    2 shared publications
  • Guadalupe Lima

    Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    2 shared publications
  • H. Fragoso-Loyo

    Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    2 shared publications
  • L. Llorente

    Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    2 shared publications
  • M. Rodriguez-Armida

    Department of Internal Medicine, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico

    2 shared publications

Latest Publications

  • Subacute Thyroiditis

    by Pamela Munguia Realpozo, Juan Jakez Ocampo, Socorro Méndez Martínez, Mario García Carrasco

  • Exhausted T cells in systemic lupus erythematosus patients in long-standing remission

    by G Lima, F Treviño-Tello, Y Atisha-Fregoso, L Llorente, H Fragoso-Loyo, J Jakez-Ocampo

    Summary: The mechanisms that drive systemic lupus erythematosus (SLE) patients to achieve remission are unknown; one possible explanation might be T cell exhaustion. The aim of the present study was to measure CD4+ and CD8+ T cell exhaustion in SLE patients in prolonged remission (PR-SLE) and compared them with patients with active SLE (Act-SLE) and healthy subjects. We included 15 PR-SLE patients, 15 Act-SLE and 29 healthy subjects. T cell exhaustion was determined by flow cytometry according to the expression of programmed cell death 1 (PD)-1, T cell immunoglobulin and mucin 3 (Tim-3), natural killer cell receptor (2B4), eomesodermin (EOMES) and T-box transcription factor TBX21 (T-bet) in CD4+ and CD8+ T cells. Dimensionality reduction using the T-distributed stochastic neighbor-embedding algorithm and clustering analysis was used for the identification of relevant populations. Percentages of CD3+, CD4+ and CD8+ T cells were similar among groups. We identified five subpopulations of CD8+ and seven of CD4+ cells. The CD4+T-bet+CD45RO+ cells identified in the unsupervised analysis were significantly increased in PR-SLE versus Act-SLE [median = 0·20, interquartile range (IQR) = 1·74–30·50 versus 1·68, IQR = 0·4–2·83; P < 0·01]. CD4+EOMES+ cells were also increased in PR-SLE versus Act-SLE (5·24, IQR = 3·38–14·70 versus 1·39, IQR = 0·48–2·87; P < 0·001). CD8+EOMES+ cells were increased in PR-SLE versus Act-SLE (37·6, IQR = 24·9–53·2 versus 8·13, IQR = 2·33–20·5; P < 0·001). Exhausted and activated T cells presented an increased frequency of PD-1, CD57 and EOMES in SLE patients versus healthy subjects. Some subpopulations of T cells expressing markers associated with exhaustion are increased in patients in remission, supporting T cell exhaustion as a tolerance mechanism in SLE. Exhaustion of specific populations of T cells might represent a potential therapeutic tool that will contribute to the goal of achieving sustained remission in these patients.


  • Correction: Clinical characteristics of systemic lupus erythematosus patients in long-term remission without treatment

    by J. Jakez-Ocampo, M. Rodriguez-Armida, H. Fragoso-Loyo, G. Lima, L. Llorente, Y. Atisha-Fregoso

    The original published version of the above article contained errors in Key Points and Conclusion sections.

  • Clinical characteristics of systemic lupus erythematosus patients in long-term remission without treatment

    by J. Jakez-Ocampo, M. Rodriguez-Armida, H. Fragoso-Loyo, G. Lima, L. Llorente, Y. Atisha-Fregoso

    Objective To describe the clinical and serological characteristics of patients with SLE who reached a state of sustained remission for more than 10 years in the absence of treatment. Methods From a retrospective cohort of 2121 patients, 44 cases with sustained remission (PtRem) were identified and compared with 88 patients whose course has been chronically active (PtAct).The clinical and serological characteristics were analyzed, as well as the treatment of each group at the beginning of the disease and during its evolution. Results Older age at disease onset was associated with a tendency to reach a state of prolonged remission. These patients also had a higher frequency of thrombocytopenia at the beginning of the disease 34.1% vs 10.2% (p < 0.001). PtAct had a significantly higher initial SLEDAI compared with cases (10.4 ± 5.6 vs 14.1 ± 5.8; p < 0.001). PtRem had a higher initial frequency of anti-β2 GP1 IgG antibodies. Also, 25% of these patients were serologically active. We did not find differences in the initial treatment between both groups. The accumulated damage measured by SLICC/ACR damage index at the end of the study was significantly less in the patients who remained in prolonged remission. Conclusions Although patients with SLE who achieve prolonged remission have some different characteristics at baseline compared with PtAct, it is not possible to identify a characteristic phenotype for the former. Achieving a state of prolonged remission should always be the goal in patients with SLE. Key Points • SLE patients can reach a very prolonged state of remission, free of treatment, including antimalarials, for at least 10 years. • Venous thromboembolism and thrombocytopenia are commonly present in patients that achieved remission. • The presence of serological markers of activity, even after 10 years in remission, is a risk factor for relapse.


  • The role of socioeconomic status in the susceptibility to develop systemic lupus erythematosus in Mexican patients

    by Norma Alicia Salgado-Galicia, Susana Hernández-Doño, Daniela Ruiz-Gómez, Juan Jakez-Ocampo, Joaquín Zúñiga, Gilberto Vargas-Alarcón, Víctor Acuña, María Teresa Hernández, José Eduardo Márquez-García, Maricela García-Lechuga, et al.

    Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disorder for which Major Histocompatibility Complex (MHC) genes are well-identified as risk factors. SLE patients have different phenotypes or clinical presentations, which vary among Mexicans. This variation could be explained by ethnicity and admixture. Since socioeconomic status probably limits and change the patterns of migration, this factor could favor inbreeding and homogamy in some geographic areas. Consequently, it could alter or restrict the possibilities of admixture too. Therefore, the socioeconomic status may also have implications in the susceptibility and the clinical heterogeneity of SLE in Mexican patients.


  • Open Access

    Expression of CXCL12 receptors in B cells from Mexican Mestizos patients with systemic lupus erythematosus

    by Vincent Biajoux, Alexandre Bignon, Christelle Freitas, Valérie Martinez, Marcus Thelen, Guadalupe Lima, Juan Jakez-Ocampo, Dominique Emilie, Luis Llorente, Karl Balabanian

    Background: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by B-cell hyper-reactivity and the production of pathogenic anti-nuclear-directed auto-antibodies (Abs). B-cell ontogeny is partly dependent on the CXCL12/CXCR4 axis for which the contribution to SLE pathogenesis remains unclear. CXCR7, the novel receptor for CXCL12, is differentially expressed among memory B-cell subsets. However, its biological role in SLE remains to be explored. Methods: Relative CXCR4 and CXCR7 expression levels were compared by quantitative PCR in leukocytes from blood samples of 41 Mexican Mestizos patients with SLE and 45 ethnicity-matched healthy subjects. Intracellular and membrane expression of both receptors was analyzed by flow cytometry in naive and Ab-secreting B cells. B-cell responsiveness to CXCL12 was investigated using Transwell-based chemotaxis assays. Data were analyzed using the Kruskal-Wallis test for comparisons of values amongst healthy controls and patients with inactive or active SLE, and non-parametrically using the Mann–Whitney U-test for multiple comparisons and unpaired samples. Correlations were determined by Spearman’s ranking. Result: SLE leukocytes displayed reduced levels of CXCR4 and CXCR7 transcripts. In SLE patients, a significant defect in CXCR4 expression was detected at the surface of naive and Ab-secreting B cells, associated with an abnormal intracellular localization of the receptor. CXCR7 predominantly localized in cytosolic compartments of B cells from healthy and SLE individuals. Disease activity did not impact on these expression patterns. Altered receptor compartmentalization correlated with an impaired CXCL12-promoted migration of SLE B cells. Conclusions: Our data highlight a down-regulation of CXCL12 receptors on circulating B cells from SLE patients that likely influences their migratory behavior and distribution.


  • Juvenile idiopathic arthritis and Wegener's Granulomatosis – Causal or casual acquaintances?

    by Juan Jakez-Ocampo, Jacqueline Ramírez, Carmen María Paulín-Vera, Luis Felipe Flores-Suárez, Edgardo Reyes, Luis Llorente